MGI is pleased that the jury verdict in the United States District Court for the District of Delaware supported all our claims, including:

1. Illumina willfully infringed U.S. Patent Nos. 9,222,132 and 10,662,473 owned by Complete Genomics, which is a US subsidiary of MGI.

2. The jury also found that Illumina's asserted claims of all three patents are invalid.

3. MGI was awarded approximately $334 million for past damages by Illumina.

The protection of intellectual property is very important to life science and biotechnology companies around the world, and it is also a value that MGI has always adhered to. MGI maintains its unwavering commitment to accelerating the industry development and providing our customers with "the right to another choice". Through our open and inclusive approach to innovation, we will work closely with industry partners to continue developing advanced genetic sequencing instruments to improve people's health.

For Chinese version statement: https://www.mgi-tech.com/news/464/